scholarly journals A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer

2019 ◽  
Vol 10 (23) ◽  
pp. 5744-5753 ◽  
Author(s):  
Siteng Chen ◽  
Ning Zhang ◽  
Jialiang Shao ◽  
Tao Wang ◽  
Xiang Wang
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Urinary Bladder ◽  
Urinary Bladder Cancer ◽  
Gene Signature ◽  
Novel Gene

scholarly journals Survival of patients with urinary bladder cancer in Jordan, 2005–2014

2021 ◽  
Vol 27 (07) ◽  
pp. 648-655
Author(s):  
Nour Abdo ◽  
Majd Alsoukhni ◽  
Anwar Batieha ◽  
Kamal Arqoub
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Urinary Bladder ◽  
National Level ◽  
Urinary Bladder Cancer ◽  
Developed Countries ◽  
Cancer Data ◽  
Factors Associated ◽  
Survival Probabilities ◽  
Significant Difference

Background: Urinary bladder cancer is the fourth most common cancer in Jordan. No research on survival from bladder cancer at the national level has been conducted before. Aims: This study aimed to estimate the probability of survival in patients with bladder cancer in Jordan and identify factors associated with survival. Methods: Data were obtained from the database of the Jordan cancer registry. All cases of urinary bladder cancer in Jordanians registered during 2005–2014 were included in the study (n = 2139). Data collected for each case included: age, sex, date of diagnosis, and stage and grade at diagnosis. Actuarial life table survival analysis was used to determine the overall survival probabilities. Cox proportional hazard regression was used to identify independent factors associated with survival. Results: The overall 1-, 3-, 5- and 10-year survival probabilities for urinary bladder cancer were 85%, 73%, 69% and 59%, respectively (standard error = 0.01 for each). No significant difference in survival probabilities was found between males and females (P = 0.642). The overall survival probabilities decreased significantly as age at diagnosis increased (P < 0.005). Better survival was observed in patients with early stage and well differentiated tumours at diagnosis. Conclusions: The survival of patients with bladder cancer in Jordan is comparable to that reported from developed countries. A high percentage of data was missing and the reporting of some variables was inconsistent. To improve the quality of cancer data, regular training is needed for hospital focal points on recording complete data

scholarly journals Retrospective analysis of clinico-epidemiological factors and clinical outcome in patients with urinary bladder carcinoma

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
E M Elsheikh ◽  
D R D Ibrahim ◽  
O M Abdelrahman ◽  
H M Ali
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Adjuvant Chemotherapy ◽  
Urinary Bladder ◽  
Cell Carcinoma ◽  
Performance Status ◽  
Transitional Cell ◽  
Urinary Bladder Cancer ◽  
Tumor Stage ◽  
Treatment Modalities

Abstract Background Bladder cancer ranks ninth in worldwide cancer incidence and it is the second most common malignancy among Egyptian males. Urothelial carcinoma (UC) of the bladder (previously known as transitional cell carcinoma; TCC)is the predominant histologic type, the two most well-established risk factors for bladder are cigarette smoking and occupational exposure to urothelial carcinogens. Aim of the Work To analyze retrospectively the clinico-pathological features of urinary bladder cancer patients treated in Clinical Oncology Department of Ain Shams University Hospitals in Egypt. Patients and Methods All 127 eligible patients fulfilling the inclusion criteria and the medical sheets were reviewed including history, clinical examination, routine laboratory tests, radiological investigations, and follow up. Several prognostic factors were analyzed in our study including age, sex, performance status, tumor size, site, grade, extent of surgery and type of treatment as regard chemotherapy and radiotherapy. Results Among the included 127 patients, populatge ranged from 30 to 75 years. Males represented 81.9 % of the patients with a male to female ratio of 4:1. Eastern Cooperative Oncology Group (ECOG) performance status of patients at presentation was ECOG 1 in 82 patients (64.6%). The majority of the studied population presented with haematuria. The most common histological subtype in biopsied specimens was transitional cell carcinoma in 75.5% of the patients.78 patients presented with non-metastatic and 47 patients with metastatic urinary bladder cancer. The median progression-free survival (PFS) was found to be 17 months and similarly the median overall survival (OS) was 17 months. In our study we found a significant correlation between age, performance status (PS), smoking, tumor stage and the treatment modalities such as surgery and adjuvant chemotherapy with the overall survival. Conclusion The epidemiology of bladder cancer was dramatically shifted in Egypt with a lower incidence of squamous cell carcinoma (SCC), a greater incidence of TCC and older age at diagnosis. Age, PS, smoking, tumor stage and the treatment modalities such as surgery and adjuvant chemotherapy were proved to affect the overall survival.

scholarly journals The value of clinical prognostic factors for survival in patients with invasive urinary bladder cancer

Medicina ◽  
2010 ◽  
Vol 46 (5) ◽  
pp. 305 ◽  
Author(s):  
Jolita Asadauskienė ◽  
Eduardas Aleknavičius ◽  
Teresė Želvienė ◽  
Feliksas Jankevičius
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Prognostic Factors ◽  
Urinary Bladder ◽  
Radical Cystectomy ◽  
Significant Influence ◽  
Univariate Analysis ◽  
Urinary Bladder Cancer ◽  
Group Completion ◽  
Cystectomy Group

The aim of the study was to evaluate the value of clinical prognostic factors for survival of patients with invasive urinary bladder cancer treated with radical cystectomy, chemotherapy, and radiotherapy. Material and methods. A total of 115 patients with invasive urinary bladder cancer were analyzed. Twenty-three patients with invasive urinary bladder cancer (pT2–T4) were treated according to the protocol of a prospective clinical study. In all the cases, transurethral resection was followed by radiation and chemotherapy. A total dose of 54–60 Gy of radiotherapy was delivered by daily fractions of 1.8–2.0 Gy each. Simultaneous chemotherapy was started on the same day as radiotherapy; gemcitabine at a dose of 175–300 mg/m2 was delivered once a week intravenously for 6 weeks. Individual patient data was analyzed in a retrospective part of the study. Radical cystectomy was performed to 46 patients with invasive urinary bladder cancer, and radiotherapy was delivered to 46 patients. Inclusion criteria for patients into a prospective or retrospective trial were equal. We evaluated a prognostic value of various clinical factors for patients treated with radical cystectomy, chemoradiation with gemcitabine, and radiation alone. Results. The 3-year overall survival in the cystectomy group was 51.1%, in the chemoradiation group 38.0%, and in the radiotherapy group 26.9% (P=0.001). In univariate analysis in the chemoradiation group, completion of treatment according to the protocol showed a significant influence on overall survival (P=0.03). In the radiation group, completion of treatment according to the protocol showed a significant influence on overall survival too (P=0.01). In the radical cystectomy group, an important factor was a complete or incomplete TUR (P=0.02). Multivariate analysis showed a significance of hydronephrosis (P=0.03) and T stage (P=0.04) in the radiation therapy group. Comorbidity was found to be an independent prognostic factors in the chemoradiation group (P=0.02). Conclusions. The best 3-year overall survival was in the radical cystectomy group. Chemoradiation with gemcitabine could be offered as an alternative to patients refusing cystectomy. Better overall survival in the chemoradiation group was for patients without comorbidities and when treatment protocol was completed.

scholarly journals Survival of patients with urinary bladder cancer in Jordan, 2005–2014

2021 ◽  
Vol 27 (07) ◽  
pp. 648-655
Author(s):  
Nour Abdo ◽  
Majd Alsoukhni ◽  
Anwar Batieha ◽  
Kamal Arqoub
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Urinary Bladder ◽  
National Level ◽  
Urinary Bladder Cancer ◽  
Developed Countries ◽  
Cancer Data ◽  
Factors Associated ◽  
Survival Probabilities ◽  
Significant Difference

Background: Urinary bladder cancer is the fourth most common cancer in Jordan. No research on survival from bladder cancer at the national level has been conducted before. Aims: This study aimed to estimate the probability of survival in patients with bladder cancer in Jordan and identify factors associated with survival. Methods: Data were obtained from the database of the Jordan cancer registry. All cases of urinary bladder cancer in Jordanians registered during 2005–2014 were included in the study (n = 2139). Data collected for each case included: age, sex, date of diagnosis, and stage and grade at diagnosis. Actuarial life table survival analysis was used to determine the overall survival probabilities. Cox proportional hazard regression was used to identify independent factors associated with survival. Results: The overall 1-, 3-, 5- and 10-year survival probabilities for urinary bladder cancer were 85%, 73%, 69% and 59%, respectively (standard error = 0.01 for each). No significant difference in survival probabilities was found between males and females (P = 0.642). The overall survival probabilities decreased significantly as age at diagnosis increased (P < 0.005). Better survival was observed in patients with early stage and well differentiated tumours at diagnosis. Conclusions: The survival of patients with bladder cancer in Jordan is comparable to that reported from developed countries. A high percentage of data was missing and the reporting of some variables was inconsistent. To improve the quality of cancer data, regular training is needed for hospital focal points on recording complete data.

777: Tissue Microarray Analysis of pAkt, PTEN and L-Plastin in Urinary Bladder Cancer

2005 ◽  
Vol 173 (4S) ◽  
pp. 211-211
Author(s):  
Loleta D. Harris ◽  
Tomasz Tuziak ◽  
Jorge De Lo Cerda ◽  
Anita L. Sabichi ◽  
Ying Yang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Tissue Microarray ◽  
Microarray Analysis ◽  
Urinary Bladder Cancer ◽  
Tissue Microarray Analysis
Sign in / Sign up

Export Citation Format

Share Document